Weaponized Pathogens and the SARS-CoV-2 Pandemic
Keywords:avian influenza (HPAI), bioweapons research, coronaviruses, COVID-19 pandemic, chronic noncommunicable diseases, dual use research, flu vaccines, gain of function, H1N1, H5N1, H7N9, Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS), SARS-CoV-2, weaponized pathogens
This review zeros in on the aspect of vaccine theory, practice, and research that is the most dangerous, the most controversial, and that is at the epicenter of the alleged SARS-CoV-2 “pandemic”. Regardless whether the “pandemic” itself is real or an illusion manufactured out of fear by vested interests, it is central to ethics and policy discussions seeking to understand bioweapons research in general. The official involvement of the USA in civilian bioweapons research dates at least from World War II under President Franklin Delano Roosevelt. The historical records, cloaked in secrecy until after the Anthrax mailing of 2001, reveal an intimate connection to vaccine research and development, its governmental protection from public scrutiny, and from citizen initiated lawsuits. It is an industry that has released dangerous weaponized pathogens by accident and by sinister designs supposedly compensated in the peace-loving nations by unrealistic hopes in non-existent counter-measures for outbreaks, including epidemiological tracking after the fact, vaccines being researched to counter the weaponization of pathogens being studied, immunity enhancing drugs, and downstream hoped for blood sera containing antibodies. Critical questions concern the ratio of real-risks to hoped-for-benefits, the “mitigating” measures “governments” (especially in the USA) have supposedly established to prevent pandemic outbreaks from bioweapons research, and how all that has played out in the instance of SARS-CoV-2.
- 2021-01-05 (2)
- 2021-01-05 (1)
How to Cite
Copyright (c) 2021 John W. Oller, Jr.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The copyright for materials in this journal, IJVTPR, is owned by the author. The author, however, grants first right of publication to the journal, IJVTPR and assures the editorial staff of the journal that the work submitted has not simultaneously been submitted to any other journal, nor is it under consideration for publication by any other journal. If any portion of the work submitted has appeared elsewhere, the quoted material is properly cited and credit is given to the original publisher. The submitting author (or the principal and corresponding author of the work) also assures the editors of IJVTPR that he or she has obtained all required written permissions from any quoted authors or publishers of quoted materials. The submitting author also agrees to hold IJVTPR and its editorial staff harmless from any infractions of copyright law that may be discovered at any time in the future in the submitted work. The author assures the editorial staff at IJVTPR that none of the work submitted is plagiarized, and that any recycled or precycled material by the author is identified as such with proper credits in the text to any other parties holding a copyright interest in the quoted material.